Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Denosumab versus zoledronic acid for skeletal-related events in breast cancer patients with bone metastases

SABCS 2009

9 - 13 Sep 2009

Published: 28 Jan 2010

Views: 9185

Rating:

Save

Dr Alison Stopeck - University of Arizona Cancer Center

Among patients with bone metastasis from breast cancer, denosumab was superior to zoledronic acid in reducing the incidence of complications from bone metastases. Denosumab prevented more events, was better tolerated and is more convenient for patients. Official San Antonio Breast Cancer Symposium press conference.

Categories:
Breast

Related Videos

Pembrolizumab improves breast cancer outcomes regardless of age or menopausal...

Dr Javier Cortes - International Breast Cancer Center, Barcelona, Spain

Pembrolizumab improves breast cancer outcomes regardless of age or menopausal status ( Dr Javier Cortes - International Breast Cancer Center, Barcelona, Spain )

Exercise positively effects symptom burden and quality of life of metastatic...

Dr Anouk Hiensch - UMC Utrecht, Utrecht, Netherlands

Exercise positively effects symptom burden and quality of life of metastatic breast cancer patients ( Dr Anouk Hiensch - UMC Utrecht, Utrecht, Netherlands )

Using AI to identify patients at increased risk of side effects from radiation...

Dr Tim Rattay - University of Leicester Cancer Research Centre, Leicester, UK

Using AI to identify patients at increased risk of side effects from radiation treatment for breast cancer ( Dr Tim Rattay - University of Leicester Cancer Research Centre, Leicester, UK )

Implementation of the Choosing Wisely Africa List in 3 Countries

Dr Sarah Kutika Nyagabona - Muhimbili National Hospital, Dar es Salaam, Tanzania

Implementation of the Choosing Wisely Africa List in 3 Countries ( Dr Sarah Kutika Nyagabona - Muhimbili National Hospital, Dar es Salaam, Tanzania )

Adding atezolizumab to adjuvant chemotherapy for stage II and III triple...

Dr Michail Ignatiadis - Institut Jules Bordet, Brussels, Belgium

Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy ( Dr Michail Ignatiadis - Institut Jules Bordet, Brussels, Belgium )

T-DM1 shows promise in treating unresectable locally advanced or metastatic...

Dr Sara Hurvitz - University of Washington, Seattle, USA

T-DM1 shows promise in treating unresectable locally advanced or metastatic HER2-positive breast cancer ( Dr Sara Hurvitz - University of Washington, Seattle, USA )

ASCO and its Sub-Saharan African outreach programme

Dr Julie Gralow - Chief Medical Officer, American Society of Clinical Oncology...

ASCO and its Sub-Saharan African outreach programme ( Dr Julie Gralow - Chief Medical Officer, American Society of Clinical Oncology (ASCO), USA )

CDK-4/6 inhibitors with endocrine treatment for metastatic breast cancer

Dr Sitna Mwanzi - Kenyatta National Hospital, Nairobi, Kenya

CDK-4/6 inhibitors with endocrine treatment for metastatic breast cancer ( Dr Sitna Mwanzi - Kenyatta National Hospital, Nairobi, Kenya )

SABCS 2023: Highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

SABCS 2023: Highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

More from ecancer